| NSCLC | Non-small-cell lung cancer |
| SCLC | Small-Cell Lung Cancer |
| LC | Lung Cancer |
| CT | Computed Tomography |
| MRI | Magnetic Resonance Imaging |
| US | Ultrasound |
| NGS | Next-generation Sequencing |
| CNS | Central nervous system |
| ctDNA | Circulating tumor DNA |
| FDG-PET | 18F-deoxyglucose-positron emission tomography |
| GLUT | Glucose transporter |
| mTORC1 | Mammalian target of rapamycin complex 1 |
| HIF | Hypoxia-inducible factor |
| HK | Hexokinase |
| PDAC | Pancreatic ductal adenocarcinoma |
| TCA | Tricarboxylic acid |
| GSH | Glutathione |
| S1P | Sphingosine-1-phosphate |
| LPE | Lysophosphatidylethanolamine |
| LDCT | Low-dose computed tomography |
| NMR | Nuclear magnetic resonance |
| MS | Mass spectrometry |
| MALDI-MSI | Matrix-assisted laser desorption/ionization mass spectrometric imaging |
| MRSI | Magnetic resonance spectroscopic imaging |
| HRMAS MRS | High-resolution magic angle spinning magnetic resonance spectroscopy |
| RRLC | Rapid resolution liquid chromatography |
| TMAO | Trimethylamine N-oxide |
| MWA | Microwave ablation |
| MVDA | Multivariate data analysis |
| ADMA | Asymmetric dimethylarginine |
| HC | Healthy control |
| PLC | Primary lung cancer |
| SLC | Secondary lung cancer |
| ROI | Region of interest |
| IBSI | Imaging Biomarker Standardization Initiative |
| GLCM | Gray-level co-occurrence matrices |
| GLRLM | Gray-level run-length matrices |